Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer - PubMed (original) (raw)
Clinical Trial
. 2007 May 15;67(10):5033-41.
doi: 10.1158/0008-5472.CAN-06-3332.
Stephanie T Page, Daniel W Lin, Ladan Fazli, Ilsa M Coleman, Lawrence D True, Beatrice Knudsen, David L Hess, Colleen C Nelson, Alvin M Matsumoto, William J Bremner, Martin E Gleave, Peter S Nelson
Affiliations
- PMID: 17510436
- DOI: 10.1158/0008-5472.CAN-06-3332
Clinical Trial
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer
Elahe A Mostaghel et al. Cancer Res. 2007.
Abstract
Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating suppression of prostatic androgen activity at the target tissue and molecular level. We determined the efficacy and consistency of medical castration in suppressing prostatic androgen levels and androgen-regulated gene expression. Androgen levels and androgen-regulated gene expression (by microarray profiling, quantitative reverse transcription-PCR, and immunohistochemistry) were measured in prostate samples from a clinical trial of short-term castration (1 month) using the gonadotropin-releasing hormone antagonist, Acyline, versus placebo in healthy men. To assess the effects of long-term ADT, gene expression measurements were evaluated at baseline and after 3, 6, and 9 months of neoadjuvant ADT in prostatectomy samples from men with localized prostate cancer. Medical castration reduced tissue androgens by 75% and reduced the expression of several androgen-regulated genes (NDRG1, FKBP5, and TMPRSS2). However, many androgen-responsive genes, including the androgen receptor (AR) and prostate-specific antigen (PSA), were not suppressed after short-term castration or after 9 months of neoadjuvant ADT. Significant heterogeneity in PSA and AR protein expression was observed in prostate cancer samples at each time point of ADT. Medical castration based on serum testosterone levels cannot be equated with androgen ablation in the prostate microenvironment. Standard androgen deprivation does not consistently suppress androgen-dependent gene expression. Suboptimal suppression of tumoral androgen activity may lead to adaptive cellular changes allowing prostate cancer cell survival in a low androgen environment. Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment.
Similar articles
- Androgen deprivation therapy: past, present and future.
Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Schröder F, et al. BJU Int. 2012 Jun;109 Suppl 6:1-12. doi: 10.1111/j.1464-410X.2012.11215.x. BJU Int. 2012. PMID: 22672120 Review. - [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. Mottet N, et al. Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Actas Urol Esp. 2011. PMID: 21757258 Spanish. - Persistent intraprostatic androgen concentrations after medical castration in healthy men.
Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Page ST, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. doi: 10.1210/jc.2006-0968. Epub 2006 Aug 1. J Clin Endocrinol Metab. 2006. PMID: 16882745 Clinical Trial. - Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA, Yen AE, Weigel NL. Shafi AA, et al. Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.
Cited by
- The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells.
Huo C, Kuo YY, Lin CY, Shiah SG, Li CY, Huang SP, Chen JK, Wang WC, Kung HJ, Chuu CP. Huo C, et al. Cancer Med. 2024 Aug;13(16):e70106. doi: 10.1002/cam4.70106. Cancer Med. 2024. PMID: 39149855 Free PMC article. - Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.
Martin-Caraballo M. Martin-Caraballo M. Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171. Int J Mol Sci. 2024. PMID: 38673756 Free PMC article. Review. - Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.
Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, Lou W, Lombard AP, Liu C, Gao AC. Schaaf ZA, et al. Cancers (Basel). 2023 Nov 3;15(21):5273. doi: 10.3390/cancers15215273. Cancers (Basel). 2023. PMID: 37958444 Free PMC article. - Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.
Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, Taïeb D, Rocchi P. Le TK, et al. Cancers (Basel). 2023 Oct 19;15(20):5047. doi: 10.3390/cancers15205047. Cancers (Basel). 2023. PMID: 37894414 Free PMC article. Review. - Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, Ong CJ. Yenki P, et al. Endocr Relat Cancer. 2023 Nov 6;30(12):e230010. doi: 10.1530/ERC-23-0010. Print 2023 Dec 1. Endocr Relat Cancer. 2023. PMID: 37800655 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- K23AG027238-01A1/AG/NIA NIH HHS/United States
- T32 CA09515-21/CA/NCI NIH HHS/United States
- K23 AG027238/AG/NIA NIH HHS/United States
- U54 HD42454/HD/NICHD NIH HHS/United States
- P50CA97186/CA/NCI NIH HHS/United States
- K23 CA122820-01/CA/NCI NIH HHS/United States
- K23 AG027238-01A1/AG/NIA NIH HHS/United States
- RR0163/RR/NCRR NIH HHS/United States
- DK65204/DK/NIDDK NIH HHS/United States
- DK65083/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous